Literature DB >> 25806164

A strong step forward in maintenance therapy for non-small cell lung cancer treatment.

Edgardo S Santos1, Tarek Mekhail2.   

Abstract

Entities:  

Year:  2012        PMID： 25806164      PMCID： PMC4367566          DOI： 10.3978/j.issn.2218-6751.2012.04.01

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  9 in total

Review 1.  Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy.

Authors:  Thomas E Stinchcombe; Mark A Socinski
Journal:  J Thorac Oncol       Date:  2009-02       Impact factor: 15.609

2.  Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.

Authors:  Luis Paz-Ares; Filippo de Marinis; Mircea Dediu; Michael Thomas; Jean-Louis Pujol; Paolo Bidoli; Olivier Molinier; Tarini Prasad Sahoo; Eckart Laack; Martin Reck; Jesús Corral; Symantha Melemed; William John; Nadia Chouaki; Annamaria H Zimmermann; Carla Visseren-Grul; Cesare Gridelli
Journal:  Lancet Oncol       Date:  2012-02-16       Impact factor: 41.316

3.  Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

Authors:  Mark A Socinski; Michael J Schell; Amy Peterman; Kamal Bakri; Steven Yates; Robert Gitten; Paul Unger; Joanna Lee; Ji-Hyun Lee; Maureen Tynan; Martha Moore; Merrill S Kies
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

4.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

5.  Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.

Authors:  Panos M Fidias; Shaker R Dakhil; Alan P Lyss; David M Loesch; David M Waterhouse; Jane L Bromund; Ruqin Chen; Maria Hristova-Kazmierski; Joseph Treat; Coleman K Obasaju; Martin Marciniak; John Gill; Joan H Schiller
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

6.  Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.

Authors:  Tudor Ciuleanu; Thomas Brodowicz; Christoph Zielinski; Joo Hang Kim; Maciej Krzakowski; Eckart Laack; Yi-Long Wu; Isabel Bover; Stephen Begbie; Valentina Tzekova; Branka Cucevic; Jose Rodrigues Pereira; Sung Hyun Yang; Jayaprakash Madhavan; Katherine P Sugarman; Patrick Peterson; William J John; Kurt Krejcy; Chandra P Belani
Journal:  Lancet       Date:  2009-09-18       Impact factor: 79.321

7.  Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer.

Authors:  Joon Oh Park; Sang-We Kim; Jin Seok Ahn; Cheolwon Suh; Jung Shin Lee; Joung Soon Jang; Eun Kyung Cho; Sung Hyun Yang; Jin-Hyuk Choi; Dae Seog Heo; Suk Young Park; Sang Won Shin; Myung Ju Ahn; Jong Seok Lee; Young Ho Yun; Jae-Won Lee; Keunchil Park
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

8.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

9.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Authors:  Robert Pirker; Jose R Pereira; Aleksandra Szczesna; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Ihor Vynnychenko; Keunchil Park; Chih-Teng Yu; Valentyn Ganul; Jae-Kyung Roh; Emilio Bajetta; Kenneth O'Byrne; Filippo de Marinis; Wilfried Eberhardt; Thomas Goddemeier; Michael Emig; Ulrich Gatzemeier
Journal:  Lancet       Date:  2009-05-02       Impact factor: 79.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.